Guruprasad P. Aithal

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Matthew J. Armstrong, Piers Gaunt, Guruprasad P. Aithal et al. · The Lancet · 2015 · 2.1K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +5

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

Guruprasad P. Aithal, Christopher P. Day, Patrick Kesteven et al. · The Lancet · 1999 · 1.2K citations

Medicine, Pharmacokinetics, Pharmacology +12

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

EASL Clinical Practice Guidelines: Drug-induced liver injury

Raúl J. Andrade, Guruprasad P. Aithal, Einar S. Björnsson et al. · Journal of Hepatology · 2019 · 1.1K citations

Medicine, Pharmacology, Pharmacotherapy +14

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

Ann K. Daly, Peter T. Donaldson, Pallav Bhatnagar et al. · Nature Genetics · 2009 · 1K citations

Life Sciences, Genetics, Pharmacology +14